Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
Фаза 4
Завершено
NCT03061006
| Заболевание | Dementia, Cognition Disorders, Cerebral Ischemic Events |
|---|
| Фаза | Фаза 4 |
|---|
| Спонсор | Intermountain Health Care, Inc. |
|---|
| Статус | Завершено |
|---|
| Участники | 101 участн. |
|---|
| Вмешательство | Dabigatran Etexilate, Warfarin |
|---|
| Дата начала | 30.03.2017 |
|---|
| Дата завершения | 15.03.2021 |
|---|
| Публикация результатов | 12.05.2026 |
|---|
Кратко
Patients will be screened at Intermountain Medical Center and at Intermountain-affiliated anticoagulation clinics in the Salt Lake City region. Patients with non-valvular atrial fibrillation will be considered for study. After written informed consent is obtained, subjects who meet eligibility criteria will be randomized 1:1 to 2 treatment arms: Group 1: Dabigatran etexilate (150 mg BID if CrCL \> 30 mL/min, or 75 mg BID if CrCL \> 15 to 30 mL/min or per USPI; and Group 2: Warfarin (Dose-adjusted (INR 2.0 - 3.0). Assessment of kidney function every 6 months will be done for Group 1. Standard warfarin follow-up and education, based upon system criteria, will be done for Group 2. All subjects will be followed for 24 months, and will be assessed at 1-week, then 3-, 6-, 12-, 18- and 24-months post-anticoagulation visits as well as other visits deem necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit following the week 1 visit, except at the 3-month visit when only one questionnaire will be administered. To determine brain volume and characteristic changes representative
Number of Participants With Incident Dementia Determined by a Formal Diagnosis of Dementia by a Neurologist
24 months · Participants
| Dabigatran Etexilate | 0 Participants |
|---|
| Warfarin | 0 Participants |
|---|
Number of Participants With Moderate Decline in Cognitive Function Based on Results of the Alzheimer's Disease Assessment Scale and the Disability Assessment for Dementia.
24 months · Participants
| Dabigatran Etexilate | 5 Participants |
|---|
| Warfarin | 2 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.